The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.
Dr. C. Michael Samson, Uveitis Specialist and Principal Investigator of this study can determine if you are eligible.
You may qualify if you:
This is a fully funded trial. All research related procedures and medication will be at no cost to the patient.
To see if you qualify for the EYEGATE Study and to make an appointment, please call: Katy Tai, Clinical Research Manager at 212-979-4251.